Agappe launches Mispa Revo Plus

Agappe Diagnostics Ltd launched Mispa Revo Plus based on TRFIA technology in a hybrid event through virtual platform and offline at IMA Hall Cochin, on May 27, 2022 in presence of Dr Maria Varghese, President – IMA, Ernakulam.

This marks Agappe’s foray into immuno-fluorescence assay-based instruments. The meeting was attended by around 1300 members of the medical fraternity and business partners.

Thomas John, Managing Director, Agappe Diagnostics, speaking on the occasion of the launch emphasised on the need for wider reach across the geographies for simpler and basic diagnostic solutions, highly beneficial to rural Indian laboratories too. Agappe, by launching the Mispa Revo Plus, aims to deliver yet another platform for quicker and simplified tests in hormones, fertility, diabetes, inflammatory, and cardiac markers. He stressed the thought process of adapting and bringing in the latest technology as the core for Agappe’s research and development objectives. Agappe’s commitment to quality will continue to build the trust of the medical fraternity as the demands surge.

Vincent Miranda, Head Domestic Business, Agappe Diagnostics, and Sudhir Nair, Vice President Sales, Agappe Diagnostics, speaking during the launch event emphasised on the complete solution offered by Agappe by the combination of nephelometry and IFA platforms. This would go a long way in the empowerment of labs for the quantitative diagnosis of specific proteins, hormones, inflammatory, diabetes, fertility, and cardiac markers.
MB Bureau